CH662812A5 - Compositions injectables renfermant du metronidazole. - Google Patents

Compositions injectables renfermant du metronidazole. Download PDF

Info

Publication number: CH662812A5
Authority: CH; Switzerland
Prior art keywords: weight; particles; metronidazole; microns; suspension according
Prior art date: 1983-08-19

Application number

CH3960/84A

Other languages

English (en)

French (fr)

Inventor

John Howard Bell

Robert Paul Haslam

Andrew Lewis

Original Assignee

May & Baker Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1983-08-19

Filing date

1984-08-17

Publication date

1987-10-30

1984-08-17 Application filed by May & Baker Ltd filed Critical May & Baker Ltd

1987-10-30 Publication of CH662812A5 publication Critical patent/CH662812A5/fr

Links

VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 title claims description 58
229960000282 metronidazole Drugs 0.000 title claims description 57
239000007972 injectable composition Substances 0.000 title 1
239000002245 particle Substances 0.000 claims description 60
239000000725 suspension Substances 0.000 claims description 41
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical group OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 18
239000007900 aqueous suspension Substances 0.000 claims description 14
230000007935 neutral effect Effects 0.000 claims description 12
239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 11
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 11
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 11
239000000375 suspending agent Substances 0.000 claims description 10
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 8
239000007864 aqueous solution Substances 0.000 claims description 7
210000001124 body fluid Anatomy 0.000 claims description 7
239000010839 body fluid Substances 0.000 claims description 7
239000003795 chemical substances by application Substances 0.000 claims description 7
239000003755 preservative agent Substances 0.000 claims description 7
235000019445 benzyl alcohol Nutrition 0.000 claims description 6
239000003630 growth substance Substances 0.000 claims description 6
239000002253 acid Substances 0.000 claims description 5
241000499489 Castor canadensis Species 0.000 claims description 4
235000011779 Menyanthes trifoliata Nutrition 0.000 claims description 4
150000007513 acids Chemical class 0.000 claims description 4
230000002335 preservative effect Effects 0.000 claims description 4
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 3
NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 3
238000007046 ethoxylation reaction Methods 0.000 claims description 3
239000000787 lecithin Substances 0.000 claims description 3
235000010445 lecithin Nutrition 0.000 claims description 3
229940067606 lecithin Drugs 0.000 claims description 3
238000002360 preparation method Methods 0.000 claims description 3
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 3
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims description 2
SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims description 2
GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical class CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 claims description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
-1 allyl sucrate Chemical compound 0.000 claims description 2
235000014113 dietary fatty acids Nutrition 0.000 claims description 2
239000000194 fatty acid Substances 0.000 claims description 2
229930195729 fatty acid Natural products 0.000 claims description 2
150000004665 fatty acids Chemical class 0.000 claims description 2
229940102213 injectable suspension Drugs 0.000 claims description 2
229920001059 synthetic polymer Polymers 0.000 claims description 2
238000004806 packaging method and process Methods 0.000 claims 1
239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
238000002347 injection Methods 0.000 description 14
239000007924 injection Substances 0.000 description 14
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
239000000243 solution Substances 0.000 description 10
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
239000011780 sodium chloride Substances 0.000 description 5
238000003756 stirring Methods 0.000 description 5
239000000203 mixture Substances 0.000 description 4
239000007787 solid Substances 0.000 description 4
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical class C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 3
239000010419 fine particle Substances 0.000 description 3
239000012530 fluid Substances 0.000 description 3
239000011521 glass Substances 0.000 description 3
239000008363 phosphate buffer Substances 0.000 description 3
239000000843 powder Substances 0.000 description 3
125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 2
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 2
238000000227 grinding Methods 0.000 description 2
239000001863 hydroxypropyl cellulose Substances 0.000 description 2
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
238000000034 method Methods 0.000 description 2
238000002156 mixing Methods 0.000 description 2
229920000136 polysorbate Polymers 0.000 description 2
239000012047 saturated solution Substances 0.000 description 2
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
230000000721 bacterilogical effect Effects 0.000 description 1
229960001631 carbomer Drugs 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
229960002242 chlorocresol Drugs 0.000 description 1
238000011109 contamination Methods 0.000 description 1
229930003836 cresol Natural products 0.000 description 1
239000013078 crystal Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
238000001802 infusion Methods 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000002356 laser light scattering Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
230000035800 maturation Effects 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
239000008389 polyethoxylated castor oil Substances 0.000 description 1
229910000160 potassium phosphate Inorganic materials 0.000 description 1
235000011009 potassium phosphates Nutrition 0.000 description 1
238000004321 preservation Methods 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
241001148471 unidentified anaerobic bacterium Species 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Dermatology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

CH3960/84A 1983-08-19 1984-08-17 Compositions injectables renfermant du metronidazole. CH662812A5 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB838322364A GB8322364D0 (en)	1983-08-19	1983-08-19	Compositions of matter

Publications (1)

Publication Number	Publication Date
CH662812A5 true CH662812A5 (fr)	1987-10-30

Family

ID=10547557

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CH3960/84A CH662812A5 (fr)	1983-08-19	1984-08-17	Compositions injectables renfermant du metronidazole.

Country Status (17)

Country	Link
JP (1)	JPS6067468A (da)
AU (1)	AU577055B2 (da)
BE (1)	BE900381A (da)
CA (1)	CA1214727A (da)
CH (1)	CH662812A5 (da)
DE (1)	DE3430354A1 (da)
DK (1)	DK165817C (da)
FR (1)	FR2560043B1 (da)
GB (2)	GB8322364D0 (da)
HU (1)	HU192990B (da)
IL (1)	IL72714A (da)
IT (1)	IT1213208B (da)
LU (1)	LU85511A1 (da)
NL (1)	NL8402510A (da)
NZ (1)	NZ209270A (da)
SE (1)	SE460095B (da)
ZA (1)	ZA846431B (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL194638C (nl) *	1986-12-19	2002-10-04	Novartis Ag	Hydrosol die vaste deeltjes van een farmaceutisch actieve stof bevat en farmaceutisch preparaat dat deze hydrosol bevat.
US7849856B2 (en)	2001-06-25	2010-12-14	3M Innovative Properties Company	Respirator valve

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB213928A (en) *	1923-04-06	1925-07-02	Deutsche Werke Ag	Improvements in or relating to compensated induction motors for single or polyphase alternating current
US3457348A (en) *	1966-06-27	1969-07-22	American Cyanamid Co	Stable syringeable suspensions of parenteral drugs in complex floc form
GB1430411A (en) *	1973-04-05	1976-03-31	May & Baker Ltd	Method and compositions for combating swine dysentery
US4029782A (en) *	1975-04-28	1977-06-14	Eli Lilly And Company	Cefazolin suspension for parenteral administration
GB2000025A (en) *	1977-05-14	1979-01-04	Pfizer Ltd	Nitroimidazole formulations
DE2932691A1 (de) *	1979-08-11	1981-04-09	Bayer Ag, 5090 Leverkusen	Antimykotische mittel mit hoeherer freisetzung der wirkstoffe

1983
- 1983-08-19 GB GB838322364A patent/GB8322364D0/en active Pending
1984
- 1984-08-13 IT IT8422323A patent/IT1213208B/it active
- 1984-08-15 NL NL8402510A patent/NL8402510A/nl not_active Application Discontinuation
- 1984-08-16 FR FR8412854A patent/FR2560043B1/fr not_active Expired
- 1984-08-17 DK DK397084A patent/DK165817C/da not_active IP Right Cessation
- 1984-08-17 IL IL72714A patent/IL72714A/xx unknown
- 1984-08-17 GB GB08420959A patent/GB2145088B/en not_active Expired
- 1984-08-17 LU LU85511A patent/LU85511A1/fr unknown
- 1984-08-17 CA CA000461262A patent/CA1214727A/en not_active Expired
- 1984-08-17 SE SE8404130A patent/SE460095B/sv not_active IP Right Cessation
- 1984-08-17 NZ NZ209270A patent/NZ209270A/en unknown
- 1984-08-17 AU AU32022/84A patent/AU577055B2/en not_active Ceased
- 1984-08-17 ZA ZA846431A patent/ZA846431B/xx unknown
- 1984-08-17 CH CH3960/84A patent/CH662812A5/fr not_active IP Right Cessation
- 1984-08-17 BE BE0/213510A patent/BE900381A/fr not_active IP Right Cessation
- 1984-08-17 DE DE19843430354 patent/DE3430354A1/de not_active Ceased
- 1984-08-17 HU HU843127A patent/HU192990B/hu not_active IP Right Cessation
- 1984-08-17 JP JP59170517A patent/JPS6067468A/ja active Pending

Also Published As

Publication number	Publication date
DK397084A (da)	1985-02-20
GB2145088B (en)	1986-10-08
NL8402510A (nl)	1985-03-18
AU3202284A (en)	1985-02-21
JPS6067468A (ja)	1985-04-17
CA1214727A (en)	1986-12-02
IL72714A (en)	1988-09-30
DK165817B (da)	1993-01-25
HUT35650A (en)	1985-07-29
GB8420959D0 (en)	1984-09-19
SE8404130L (sv)	1985-02-20
BE900381A (fr)	1985-02-18
FR2560043A1 (fr)	1985-08-30
FR2560043B1 (fr)	1988-08-05
SE8404130D0 (sv)	1984-08-17
GB8322364D0 (en)	1983-09-21
DE3430354A1 (de)	1985-03-07
IT1213208B (it)	1989-12-14
LU85511A1 (fr)	1985-04-24
GB2145088A (en)	1985-03-20
SE460095B (sv)	1989-09-11
AU577055B2 (en)	1988-09-15
DK165817C (da)	1993-06-21
NZ209270A (en)	1988-02-29
DK397084D0 (da)	1984-08-17
IT8422323A0 (it)	1984-08-13
HU192990B (en)	1987-08-28
ZA846431B (en)	1985-03-27

Legal Events

Date	Code	Title	Description
1995-04-28	PL	Patent ceased
2024-10-31	PL	Patent ceased

Publication	Publication Date	Title
CA2233924C (fr)	2012-08-21	Nouvelles formulations liquides stables a base de paracetamol et leur mode de preparation
EP0835105B1 (fr)	2002-03-06	Composition pharmaceutique d'amiodarone pour administration parenterale
EP2482851B1 (fr)	2020-11-11	Formulation liquide, stable, prete a l'emploi de ketoprofene
FR2761265A1 (fr)	1998-10-02	Composition pharmaceutique pour l'administration orale d'un derive du n-piperidino-3-pyrazolecarboxamide, de ses sels et de leurs solvates
FR2803203A1 (fr)	2001-07-06	Nouvelles formulations galeniques du fenofibrate
FR2853547A1 (fr)	2004-10-15	Compositions pharmaceutiques injectables contenant de la piperacilline et du tazobactame, et procede pour leur production
EP1207875A1 (fr)	2002-05-29	Preparation pharmaceutique stable d'oxaliplatine pour administration par voie parenterale
CA3234595A1 (fr)	2023-05-16	Solution pharmaceutique d'hydrocortisone pour dispositif d'injection
FR2756736A1 (fr)	1998-06-12	Compositions pharmaceutiques contenant des derives de n-sulfonyl indoline
CH662812A5 (fr)	1987-10-30	Compositions injectables renfermant du metronidazole.
KR102066108B1 (ko)	2020-01-15	페닐링을 가지는 2종 화합물을 포함하는 화장료 조성물
WO2015068105A1 (en)	2015-05-14	An improved process for manufacturing sterile ophthalmic pharmaceutical suspensions
WO2004010977A1 (fr)	2004-02-05	Procede pour diminuer la variabilite de la biodisponibilite d'un medicament a administration orale
FR3057771A1 (fr)	2018-04-27	Emulsions topiques de lidocaine et d'acides gras utiles en tant qu'analgesique, antalgique ou retardant sexuel
EP0433140B1 (fr)	1993-03-31	Nouvelle préparation pharmaceutique anti-allergique à action prolongée
JP6189437B2 (ja)	2017-08-30	注射用抗生物質製剤およびその使用方法
WO2008099068A2 (fr)	2008-08-21	Composition liquide anhydre destinee a etre incorporee a l'eau de boisson des animaux d'elevage
WO2024003503A1 (fr)	2024-01-04	Contenant en plastique comprenant une solution injectable de fentanyl
WO2001066109A1 (fr)	2001-09-13	Compositions pharmaceutiques orales contenant des derives de n-sulfonylindoline
EP2874623B1 (en)	2018-12-12	Injectable antibiotic formulations and their methods of use
FR2793412A1 (fr)	2000-11-17	Formulations galeniques d'argatroban pour administration sous-cutanee
FR2793418A1 (fr)	2000-11-17	Formulations galeniques d'agents antithrombotiques pour administration sous-cutanee
CH397955A (fr)	1965-08-31	Procédé de fabrication d'une préparation corticotropique à action prolongée